Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clazosentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 1.00 |
| ▸ | EDNRB | P24530 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clazosentan SCHEMBL1652657 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29565931 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Tezosentan SCHEMBL4525 | 0.92 | EDNRA (1.00) | EDNRAEDNRB | |
| Tezosentan SCHEMBL29194446 | 0.91 | EDNRA (0.99) | EDNRAEDNRB | |
| Tezosentan SCHEMBL387773 | 0.91 | EDNRA (0.99) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29581324 | 0.88 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29379450 | 0.88 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL1983603 | 0.88 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29581457 | 0.88 | EDNRA (0.78) | EDNRAEDNRB | |
| Clazosentan SCHEMBL6974621 | 0.88 | EDNRA (0.78) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281180-A1 | SARS-COV-2 THERAPEUTICS | Model Medicines, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-4157448-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| WO-2022159763-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |